Sternberg Z
Mol Neurobiol. 2023; 61(5):2996-3018.
PMID: 37953352
DOI: 10.1007/s12035-023-03684-2.
Ouerdane Y, Hassaballah M, Nagah A, Ibrahim T, Mohamed H, El-Baz A
Pharmaceuticals (Basel). 2022; 15(1).
PMID: 35056133
PMC: 8778520.
DOI: 10.3390/ph15010076.
Hormann P, Delcambre S, Hanke J, Geffers R, Leist M, Hiller K
Cell Death Discov. 2021; 7(1):151.
PMID: 34226525
PMC: 8257685.
DOI: 10.1038/s41420-021-00547-4.
Stansley B, Yamamoto B
Toxics. 2017; 3(1):75-88.
PMID: 29056652
PMC: 5634697.
DOI: 10.3390/toxics3010075.
Uitti R, Ahlskog J
CNS Drugs. 2015; 5(5):369-88.
PMID: 26071049
DOI: 10.2165/00023210-199605050-00006.
Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus.
Stansley B, Yamamoto B
J Pharmacol Exp Ther. 2014; 351(2):440-7.
PMID: 25212217
PMC: 4201267.
DOI: 10.1124/jpet.114.218966.
L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells.
Stansley B, Yamamoto B
Neuropharmacology. 2012; 67:243-51.
PMID: 23196068
PMC: 3638241.
DOI: 10.1016/j.neuropharm.2012.11.010.
Levodopa in the treatment of Parkinson's disease: an old drug still going strong.
Poewe W, Antonini A, Zijlmans J, Burkhard P, Vingerhoets F
Clin Interv Aging. 2010; 5:229-38.
PMID: 20852670
PMC: 2938030.
DOI: 10.2147/cia.s6456.
Optimising levodopa therapy for the management of Parkinson's disease.
Stocchi F
J Neurol. 2005; 252 Suppl 4:IV43-IV48.
PMID: 16222437
DOI: 10.1007/s00415-005-4009-4.
Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice.
Forsberg M, Juvonen R, Helisalmi P, Leppanen J, Gogos J, Karayiorgou M
Naunyn Schmiedebergs Arch Pharmacol. 2004; 370(4):279-89.
PMID: 15378229
DOI: 10.1007/s00210-004-0967-9.
The role of astroglia on the survival of dopamine neurons.
Mena M, de Bernardo S, Casarejos M, Canals S, Rodriguez-Martin E
Mol Neurobiol. 2002; 25(3):245-63.
PMID: 12109874
DOI: 10.1385/MN:25:3:245.
Emerging therapies in the pharmacological treatment of Parkinson's disease.
Korczyn A, Nussbaum M
Drugs. 2002; 62(5):775-86.
PMID: 11929331
DOI: 10.2165/00003495-200262050-00005.
Pharmacological treatment of Parkinson's disease.
Munchau A, Bhatia K
Postgrad Med J. 2000; 76(900):602-10.
PMID: 11009573
PMC: 1741769.
DOI: 10.1136/pmj.76.900.602.
Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?.
Murer M, Raisman-Vozari R, Gershanik O
Drug Saf. 1999; 21(5):339-52.
PMID: 10554050
DOI: 10.2165/00002018-199921050-00001.
Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.
LaVoie M, Hastings T
J Neurosci. 1999; 19(4):1484-91.
PMID: 9952424
PMC: 6786023.
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
Fariello R
Drugs. 1998; 55 Suppl 1:10-6.
PMID: 9483165
DOI: 10.2165/00003495-199855001-00002.
Increased plasma bilirubin in Parkinson patients on L-dopa: evidence against the free radical hypothesis?.
Scigliano G, Girotti F, Soliveri P, Musicco M, Radice D, Caraceni T
Ital J Neurol Sci. 1997; 18(2):69-72.
PMID: 9239525
DOI: 10.1007/BF01999565.
Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.
Carvey P, Pieri S, Ling Z
J Neural Transm (Vienna). 1997; 104(2-3):209-28.
PMID: 9203083
DOI: 10.1007/BF01273182.
Mortality associated with selegiline in Parkinson's disease. What do the available data mean?.
Mizuno Y, Kondo T
Drug Saf. 1997; 16(5):289-94.
PMID: 9187529
DOI: 10.2165/00002018-199716050-00001.
Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.
Walkinshaw G, Waters C
J Clin Invest. 1995; 95(6):2458-64.
PMID: 7769091
PMC: 295923.
DOI: 10.1172/JCI117946.